Chris Carpenter
InvestorExecutive Partner, Private Equity at Sofinnova Ventures
Cambridge, Massachusetts, United States
About
Chris Carpenter is an oncology physician-scientist with over two decades of clinical and laboratory experience who joined Sofinnova in 2022, focusing on clinical-stage product companies in oncology, rare diseases, and specialty therapeutics. He previously served as Chief Medical Officer at CatamaranBio and Rubius Therapeutics, and led cancer epigenetics at GlaxoSmithKline as well as drug development work at Merck. He holds a B.S. from Stanford University and M.D. and Ph.D. degrees from the University of Southern California, and is board certified in internal medicine and medical oncology.
Contact· self-published, not guessed
Invests in
Biotech
Experience
- Sofinnova InvestmentsAssociatecurrent2024 — presentMenlo Park, California, United States
- Sofinnova InvestmentsAnalyst2022 — 2024Menlo Park, California, United States
- Stanford UniversityBiology PhD Student2016 — 2022
- Stanford UniversityTeaching Assistant2018
- Maze TherapeuticsBusiness Development Consultant2020 — 2022South San Francisco, California, United States
- Mythos Biotechnology FundManaging Partner (Executor)2019 — 2020
- Mythos Biotechnology FundAnalyst2017 — 2019
- University of California, DavisLab Technician2014 — 2016
- University of California, DavisStudent Assistant2013 — 2014
- University of California, DavisUndergraduate Researcher2012 — 2013
- The Rockefeller UniversitySummer Researcher2013
Deals · 1
Atsena Therapeutics, Inc.Board seat
via Sofinnova Ventures · filed Apr 2025 · $150M raise
Attribution from SEC filings, press coverage, and firm rosters.
Other disclosed investments
Board seats
AlkeusAtsenaCapstan
Sources: the firm's website · SEC Form D filings.
Colleagues at Sofinnova Ventures
Alex Chan
Controller, Private Equity at Sofinnova Ventures
Alex Dulnev
IT Manager at Sofinnova Ventures
Amanda Phillips
Executive Assistant at Sofinnova Ventures
Anastasia Voevodin
Analyst, Public Equity at Sofinnova Ventures
Aneal Tenjarla
Partner, Associate Portfolio Manager, Public Equity at Sofinnova Ventures
Calvin Sternick
Analyst, Public Equity at Sofinnova Ventures
David Kabakoff
Executive Partner, Private Equity at Sofinnova Ventures
David Kabakoff
Partner at HealthQuest Capital
Frequently asked questions
- Who is Chris Carpenter?
- Chris Carpenter is an oncology physician-scientist with over two decades of clinical and laboratory experience who joined Sofinnova in 2022, focusing on clinical-stage product companies in oncology, rare diseases, and specialty therapeutics. He previously served as Chief Medical Officer at CatamaranBio and Rubius Therapeutics, and led cancer epigenetics at GlaxoSmithKline as well as drug development work at Merck. He holds a B.S. from Stanford University and M.D. and Ph.D. degrees from the University of Southern California, and is board certified in internal medicine and medical oncology.
- Where does Chris Carpenter work?
- Chris Carpenter is Executive Partner, Private Equity at Sofinnova Ventures.
- What does Chris Carpenter invest in?
- Chris Carpenter invests in Biotech.
- What boards does Chris Carpenter sit on?
- Chris Carpenter holds tracked board seats at Alkeus, Atsena, Atsena Therapeutics, Inc., Capstan.
- Where did Chris Carpenter go to school?
- Chris Carpenter studied at Stanford University (Doctor of Philosophy - PhD, Biology); University of California, Davis (Bachelor of Science - BS, Biochemistry and Molecular Biology).
Same school
Also attended Stanford University2,000
Peter ThielCo-founder & Partner at Founders FundReid HoffmanCo-founder of LinkedIn; Partner at GreylockKeith RaboisManaging Director at Khosla VenturesGarry TanPresident & CEO of Y CombinatorAlfred LinPartner at Sequoia CapitalAnn Miura-KoCo-founding Partner at Floodgate
+ 1,994 more
Also attended University of California, Davis194
Charles CallSLP & Venture Partner at Cottonwood Technology FundDavid PhuController at Felicis VenturesTeresa ChanChief Financial Officer at Felicis VenturesMike ZakInvestor at CRV (Charles River Ventures)Bryan EglanDirector of Business Development at Menlo VenturesScott MaxwellInvestor at OpenView Venture Partners
+ 188 more
Shared employers
Also worked at Sofinnova Investments29
Jonathan BurbaumEntrepreneur-In-Residence at The Innovation SpaceJennifer JamesManaging Director, Chief Operating Officer and Head of Investor Relations and Marketing at Thoma BravoPaul HansenFinance Director at RIT Capital PartnersRyan PanchadsaramAdvisor to the Chairman at KPCBGreg MondreCo-CEO at Silver Lake PartnersMaha KatabiGeneral Partner at Sofinnova Ventures
+ 23 more
Also worked at Stanford University788
Ann Miura-KoCo-founding Partner at FloodgateBalaji SrinivasanAngel investor and founder of The Network SchoolMartin CasadoGeneral Partner at Andreessen HorowitzMike KriegerCo-founder of Instagram; Chief Product Officer at AnthropicAndy FangCo-founder & CTO of DoorDashRyan SheaCo-founder of Blockstack (Stacks)
+ 782 more
Also worked at Maze Therapeutics9
Jeffrey FinerVenture Partner at Third Rock VenturesVyas RamananVenture Partner at Third Rock VenturesSudhir AgrawalInvestor at 82VSHugo HiltonPrincipal at Third Rock VenturesDr. Carolin AlthoffGeneral Partner - Investor & Head of ESG at Cusp CapitalAlex ColvilleCo-Founder, General Partner at age1
+ 3 more
Also worked at Mythos Biotechnology Fund6
Maxwell BikoffManaging Director at Longitude CapitalLin NingSenior Associate at Dolby Family VenturesBikoffManaging Director at Longitude CapitalChenSenior Associate at Longitude CapitalBethany ChenSenior Associate at Longitude CapitalSarah FedermanVice President, Landscape Decarbonization at Carbon Direct
